Menu
Currency
GWAS Study

Genome-Wide Association Study of Cardiovascular Resilience Identifies Protective Variation in the <i>CETP</i> Gene.

Yu C, Bakshi A, Watts GF et al.

37929782 PubMed ID
GWAS Study Type
25919 Participants
73 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

YC
Yu C
BA
Bakshi A
WG
Watts GF
RA
Renton AE
FB
Fulton-Howard B
GA
Goate AM
NP
Natarajan P
CD
Chasman DI
RL
Robman L
WR
Woods RL
GR
Guymer R
WR
Wolfe R
TL
Thao LTP
MJ
McNeil JJ
TA
Tonkin AM
NS
Nicholls SJ
LP
Lacaze P
Chapter II

Abstract

Summary of the research findings

Background The risk of atherosclerotic cardiovascular disease (ASCVD) increases sharply with age. Some older individuals, however, remain unaffected despite high predicted risk. These individuals may carry cardioprotective genetic variants that contribute to resilience. Our aim was to assess whether asymptomatic older individuals without prevalent ASCVD carry cardioprotective genetic variants that contribute to ASCVD resilience. Methods and Results We performed a genome-wide association study using a 10-year predicted ASCVD risk score as a quantitative trait, calculated only in asymptomatic older individuals aged ≥70 years without prevalent ASCVD. Our discovery genome-wide association study of N=12 031 ASCVD event-free individuals from the ASPREE (Aspirin in Reducing Events in the Elderly) trial identified 2 independent variants, rs9939224 (P&lt;5×10-8) and rs56156922 (P&lt;10-6), in the CETP (cholesteryl ester transfer protein) gene. The CETP gene is a regulator of plasma high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and lipoprotein(a) levels, and it is a therapeutic drug target. The associations were replicated in the UK Biobank (subpopulation of N=13 888 individuals aged ≥69 years without prevalent ASCVD). Carriers of the identified CETP variants (versus noncarriers) had higher plasma high-density lipoprotein cholesterol levels, lower plasma low-density lipoprotein cholesterol levels, and reduced risk of incident ASCVD events during follow-up. Expression quantitative trait loci analysis predicted the identified CETP variants reduce CETP gene expression across various tissues. Previously reported associations between genetic CETP inhibition and increased risk of age-related macular degeneration were not observed among the 3917 ASPREE trial participants with retinal imaging and genetic data available. Conclusions Common genetic variants in the CETP gene region are associated with cardiovascular resilience during aging. Registration URL: https://www.clinicaltrials.gov; Unique identifier: NCT01038583.

12,031 European ancestry individuals

Chapter III

Study Statistics

Key metrics and study information

25919
Total Participants
GWAS
Study Type
Yes
Replicated
13,888 European ancestry individuals
Replication Participants
European
Ancestry
U.K.
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.